Earlier this year, the biotech reached an agreement that blocks Samsung Bioepis from marketing its Enbrel biosimilar while patent litigation proceeds.For now, Enbrel appears to be relatively safe from an immediate threat in the U.S. That should remove a dark cloud weighing on Amgen and clear the way for pipeline wins to potentially propel the biotech stock higher.